Aussie Biotech CSL Sees Talecris Acquisition As Ticket To Grow Plasma Therapeutics
This article was originally published in The Pink Sheet Daily
Executive Summary
North Carolina biotech operates 56 plasma collection centers and two manufacturing facilities in U.S.
You may also be interested in...
Talecris’ Gamunex Gets Leg Up In CIDP
Immune globulin’s broader label sure to please merger-bound CSL.
Talecris’ Gamunex Gets Leg Up In CIDP
Immune globulin’s broader label sure to please merger-bound CSL.
Australia, New Zealand Roundup: Pharmaxis, CSL, PHARMAC
Pharmaxis Completes Long-Term Safety Study Of Bronchitol